nilutamide
nilutamide: sourced relationships with 1 company · 3 clinical trials tracked · 1 FDA decision.
nilutamide evidence translation
What we can confirm
1 FDA record · 3 tracked trials
What it means
What to watch
Prepared research question
How could nilutamide → ANIP affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| ANI PHARMACEUTICALS INC (ANIP) Reported 2016-07-15 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (3)
Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer
Primary endpoint: Overall survival (OS)
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Primary endpoint: Freedom from progression (FFP) (Phase II)
A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone in Patients With Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy
Primary endpoint: Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml)
Frequently asked questions
Which companies have sourced relationships with nilutamide?
nilutamide has dated SEC/FDA relationship records for ANI PHARMACEUTICALS INC.
How many clinical trials involve nilutamide?
BioSniper tracks 3 clinical trials involving nilutamide.
What is nilutamide's latest FDA decision?
The most recent tracked FDA decision for nilutamide is Approval, dated July 15, 2016.